Phase II Study Of E7389, Halichondrin B Analogue, In Patients With Advanced Non-Small Cell Lung Cancer, NSCLC, Who Progressed During Or After Platinum-Based Doublet Chemotherapy

NCT ID: NCT00100932

Last Updated: 2012-03-27

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE2
• Total Enrollment: 106 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2004-12-31

Brief Summary

This is a study of E7389 in patients with recurrent and/or metastatic Non-Small-Cell Lung Cancer (NSCLC) who progressed during or after treatment with a platinum agent and another chemotherapy.

Conditions

Non-Small-Cell Lung Carcinoma

Study Design

• Allocation Method: NON_RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

1

E7389 28 day cycle

Group Type: EXPERIMENTAL

E7389 28 Day Cycle

Intervention Type: DRUG

E7389 1.4 mg/m\^2 IV bolus on Days 1, 8, and 15 of a 28 day cycle.

2

E7389 21 day cycle

Group Type: EXPERIMENTAL

E7389 21 Day Cycle

Intervention Type: DRUG

E7389 1.4 mg/m\^2 IV bolus on Days 1 and 8 of a 21 day cycle.

Interventions

E7389 28 Day Cycle

E7389 1.4 mg/m\^2 IV bolus on Days 1, 8, and 15 of a 28 day cycle.

Intervention Type: DRUG

E7389 21 Day Cycle

E7389 1.4 mg/m\^2 IV bolus on Days 1 and 8 of a 21 day cycle.

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

• Patients must have a histologically or cytologically confirmed diagnosis of non-small cell lung cancer with at least one site of measurable disease by the RECIST criteria.
• Patients must have failed prior platinum-containing doublet chemotherapy. Patients who have received single agent chemotherapy with or without a subsequent taxane containing regimen may be enrolled after discussion with Sponsor.
• Patients must be ≥ 18 years of age.
• Patients must have a performance score of 0 or 1 using the ECOG performance scale.
• Patients must have a life expectancy of ≥ 3 months.
• Patients must have adequate renal function as evidenced by a serum creatinine ≤ 2.0 mg/dL or a calculated creatinine clearance ≥ 40 mL/min per the Cockcroft and Gault formula.
• Patients must have adequate hepatic function as evidenced by bilirubin ≤1.5 mg/dL and alkaline phosphatase, AST and ALT ≤ 3 times upper limit of normal, unless there is evidence of liver metastases, in which case the alkaline phosphatase, AST and ALT must be ≤ 5 times upper limit of normal.
• Patients must have adequate bone marrow function as evidenced by absolute neutrophil counts (ANC) ≥ 1.5 X 10^9/L, hemoglobin ≥ 10.0 g/dL (a hemoglobin < 10.0 g/dL would be acceptable if it can be corrected by growth factor or transfusion), and platelet count ≥ 100 X 10^9/L.
• Patients must be willing and able to comply with the protocol guidelines for the duration of the study.
• Patients must be willing and able to complete the Lung Cancer Symptom Scale (LCSS) instrument.
• The biopsy specimen (paraffin block or at least 10 unstained slides) must be available from either the initial diagnosis or any subsequent diagnostic or surgical procedure of patients participating in the pharmacogenomics sub-study only. However, no additional biopsies are obligatory for participation in this study except those required for confirmation of the diagnosis.
• Patients must give written informed consent prior to any study-specific screening procedures with the understanding that the patient may withdraw consent at any time without prejudice.

Exclusion Criteria

• Patients with pre-existing peripheral neuropathy > Grade 2
• Patients who require therapeutic doses of warfarin
• Patients who have not recovered from any chemotherapy, radiation or other therapy related toxicity deemed to be clinically significant at study entry
• Patients with active symptomatic brain metastases. Patients with central nervous system (CNS) metastases are considered eligible if they have had adequately treated brain metastases, i.e. have completed treatment (tapered off steroids) at least four weeks before starting treatment with E7389. Patients who have no evidence that the metastases are symptomatic or actively growing (no evidence of midline shift on CT scan or MRI) may be enrolled without initiation of local therapy for the CNS metastases. In this case, a repeat scan must be performed within four weeks of the original scan to ensure that disease progression is not occurring. It is not the intention of this study to treat patients with active brain metastases.
• Patients who have a positive history for HIV, active hepatitis B or active hepatitis C.
• Patients with other significant medical, or psychiatric disorders that, in the opinion of the investigator, will exclude the patient from the study for compliance or safety reasons
• Patients who have received investigational drugs, including immunotherapy, gene therapy, hormone therapy (except megestrol acetate for appetite stimulation), or other biological therapy; conventional chemotherapy or radiation therapy (except for palliation, defined as less than 10% of the bone marrow reserve and less than 20 Gy), within three weeks of E7839 enrollment
• Patients who have received non-cytotoxics (eg, gefitinib, erlotinib) within one week of E7389 enrollment
• Patients who have not recovered from major surgery within three weeks of E7389 enrollment
• Patients with severe/uncontrolled intercurrent illness/infection
• Patients with significant cardiovascular impairment (history of congestive heart failure>NYHA grade II, unstable angina or myocardial infarction within the past six months, or serious cardiac arrhythmia)
• Patients with organ allografts
• Patients with hypersensitivity to halichondrin B and/or halichondrin B-related compounds
• Patients who participated in a prior E7389 clinical trial
• Patients with second malignancy within the past 5 years, except for carcinoma in situ of the cervix or basal cell carcinoma of the skin
• Women who are pregnant or breast-feeding; woman of childbearing potential with a positive pregnancy test at screening or no pregnancy test. Women of childbearing potential unless (1) surgically sterile or (2) using adequate measures of contraception in the opinion of the Investigator. Perimenopausal women must be amenorrheic for at least 12 months or using adequate contraception to be considered of non-childbearing potential.
• Fertile men who are not willing to use contraception or fertile men with a female partner who is not willing to use contraception

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Eisai Inc.

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Dale Shuster, Ph.D.

Role: STUDY_DIRECTOR

Eisai Inc.

Locations

Gilroy, California, United States

Ocala, Florida, United States

Baltimore, Maryland, United States

Columbia, Missouri, United States

Saint Joseph, Missouri, United States

St Louis, Missouri, United States

McCook, Nebraska, United States

Canton, Ohio, United States

Dallas, Texas, United States

Fort Worth, Texas, United States

Fairfax, Virginia, United States

Norfolk, Virginia, United States

Vancouver, Washington, United States

Countries

United States

Other Identifiers

E7389-A001-202

Identifier Type: -

Identifier Source: org_study_id